EN
中文
EN
Who We Are
Newsroom
Innovation
Products
Investor Relations
Careers
Contact Us
Information Disclosure
Home
>
Investor Relations
>
Information Disclosure
H Share
VOLUNTARY ANNOUNCEMENT - ANNOUNCEMENT ON THE 2024 INVESTOR OPEN DAY EVENT
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE SUPPLEMENTAL DRUG APPLICATION FOR MENHYCIA
CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR
VOLUNTARY ANNOUNCEMENT INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE, FREEZE-DRIED
Monthly Return of Equity Issuer on Movements in Securities
THIRD QUARTERLY REPORT FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024
NOTICE OF BOARD MEETING
VOLUNTARY ANNOUNCEMENT - RECOMBINANT POLIOMYELITIS VACCINE OBTAINS CLINICAL TRIAL APPROVAL IN INDONESIA
VOLUNTARY ANNOUNCEMENT - GRANT AGREEMENT OF RECOMBINANT POLIOMYELITIS VACCINE AND RELATED COMBINED VACCINE PROJECT
Monthly Return of Equity Issuer on Movements in Securities
1
2
3
4
5
6
43
